Abstract:Background: Triple-negative breast cancer (TNBC) is aggressive and disproportionately affects Black women. Immunotherapy (IO) improves outcomes in early-stage and metastatic TNBC and has been increasingly used since the accelerated approval of atezolizumab for metastatic TNBC in March 2019. However, whether there are racial/ethnic disparities in IO receipt and oncologic outcomes for TNBC is unclear. Methods: Data came from TNBC patients in the National Cancer Database. Trends in IO use were assessed from 2017-2021. For early-stage TNBC, we included stage II-III patients with neoadjuvant chemotherapy in 2021 and performed logistic regression to examine pathologic complete response (pCR) by race/ethnicity. In the metastatic cohort, patients diagnosed with TNBC from 2019-2021 were included and examined for racial/ethnic differences in overall survival using Cox regression. Racial/ethnic groups included American Indian, Alaska Native, or Other (AIANO), Asian or Pacific Islander (API), Black, Hispanic, and White. Results: Overall, IO use increased from 5.3% in 2017 to 33.1% in 2021 for metastatic TNBC and from 4.2% in 2017 to 48.0% in 2021 for early-stage TNBC (all P-trend<.001). Of 7,655 early-stage TNBC diagnosed in 2021, 53.5% of API patients received IO, followed by 48.5% Hispanic, 48.3% AIANO, 48.2% White, and 45.9% Black. After controlling for demographic and clinical factors, there were no differences in IO use comparing API (adjusted odds ratio [AOR]=1.04; 95% CI=0.79-1.37), Hispanic (AOR=1.00; 95% CI=0.80-1.24), Black (AOR=0.96; 95% CI=0.83-1.12), AIANO (AOR=0.92; 95% CI=0.64-1.34) with White patients. However, Medicare enrollees had lower odds of IO receipt than those privately insured (AOR=0.84; 95% CI=0.70-0.99); comprehensive community programs had lower odds of IO use than academic/research programs (AOR=0.80; 95% CI=0.70-0.92). Among those who received IO, we found no difference in pCR rate by race/ethnicity. Of 4,533 metastatic TNBC diagnosed from 2019-2021, 35.4% of Hispanic patients received IO, followed by 34.3% API, 30.6% White, 26.7% AIANO, and 24.7% Black. In the adjusted model, Black patients with metastatic TNBC had lower odds of IO receipt than White patients (AOR=0.66; 95% CI=0.53-0.82) while no differences were observed between other minority and White patients. Among those who received IO, overall survival rates were similar between Black and White patients (adjusted hazard ratio=0.88; 95% CI=0.63-1.22). Conclusions: IO receipt was lower in Black patients with early-stage TNBC, which was influenced in part by facility type and insurance status – highlighting key targets to reduce these disparities. In the metastatic cohort, Black patients were less likely to receive IO even after confounder adjustment – etiologies of these disparities, such as inequitable treatment access or racial differences in PD-L1 status, require further exploration. In both cohorts, Black patients receiving IO attained equivalent outcomes to White patients, suggesting that access to IO can mitigate racial disparities in TNBC treatment outcomes. Citation Format: Jincong Q. Freeman, Dezheng Huo, Sarah P. Shubeck, Nan Chen, Sudha R. Yarlagadda, Rita Nanda, Frederick M. Howard. Immunotherapy for triple-negative breast cancer in the US: National trends, racial/ethnic disparities, and oncologic outcomes [abstract]. In: Proceedings of the 17th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2024 Sep 21-24; Los Angeles, CA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2024;33(9 Suppl) nr C035.

Racial Disparities in Time to Treatment Initiation for Stage IV Non-Small Cell Lung Cancer Patients Receiving Immunotherapy

Racial disparities in the immunotherapeutic outcomes of patients with non-small cell lung cancer (NSCLC): An in-depth systematic review and meta-analysis.

Abstract 4845: Evaluating racial disparities in immune checkpoint inhibitor survival and autoimmunity

Real-world analysis of the impact of race on immunotherapy in non-small cell lung cancers.

Racial Disparities in Young-Onset Patients with Colorectal, Breast and Testicular Cancer

Racial Disparities and Treatment Trends in a Large Cohort of Elderly Black and White Patients with Nonsmall Cell Lung Cancer.

Racial and Socioeconomic Disparities in the Delivery of Immunotherapy for Metastatic Melanoma in the United States

Disparity in Checkpoint Inhibitor Utilization among Commercially Insured Adult Patients with Metastatic Lung Cancer

Abstract C035: Immunotherapy for triple-negative breast cancer in the US: National trends, racial/ethnic disparities, and oncologic outcomes

Racial and Ethnic Disparities in Lung Adenocarcinoma Survival: A Competing-Risk Model.

Differences by race in systemic oncologic end-of-life (EOL) care among patients with cancer.

Abstract C126: Disparities in time-to-treat insured patients with newly diagnosed cancer in a vertically integrated healthcare system

Racial and socioeconomic disparities in NSCLC molecular diagnostics uptake

Evaluation of the tumor microenvironment in African American and non-Hispanic White patients with non-small cell lung cancer associated with PD-L1 expression or the presence of tertiary lymphoid structures.

Socioeconomic and Demographic Disparities in Immunotherapy Utilization for Advanced Kidney and Bladder Cancer

The real-world insights on the use, safety, and outcome of immune-checkpoint inhibitors in underrepresented populations with lung cancer

Analysis of Real-World Data to Investigate the Impact of Race and Ethnicity on Response to Programmed Cell Death-1 and Programmed Cell Death-Ligand 1 Inhibitors in Advanced Non-Small Cell Lung Cancers.

Abstract C021: Racial and socioeconomic disparities in molecular diagnostics for NSCLC patients

Racial disparities in early-stage NSCLC treatment: A Call for Action

Disparities in uptake of new FDA-approved therapies for metastatic clear cell renal cell carcinoma.

Racial differences in characteristics and prognoses between Asian and white patients with nonsmall cell lung cancer receiving atezolizumab: An ancillary analysis of the POPLAR and OAK studies